A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GSK 5733584 (Primary) ; Antineoplastics
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms BEHOLD-2
Sponsors GSK

Most Recent Events

19 Feb 2025 Planned End Date changed from 14 Apr 2028 to 3 Apr 2028.
19 Feb 2025 Planned primary completion date changed from 8 Jan 2027 to 2 Sep 2027.
19 Feb 2025 Planned initiation date changed from 13 Mar 2025 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight